구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | midazolam |
Overview Company | Alterome Therapeutics, Inc. |
Overview Modality | ADC |
Overview Target | Carcinomas |
Overview Indication | Cancer; PDAC - Pancreatic Ductal Adenocarcinoma |
Overview Phase | PHASE_1 |
Overview Status | ACTIVE |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
MoA Mechanism | ADC decoupling, FcRn recycling, target-mediated drug disposition, and lysosomal MMAE release |
MoA Biomarker | Biomarker Data |
PK/PD Species | Dog, Minipig |
PK/PD Animal (cat.) | Human, Dog, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Dog, Minipig |
Toxicology Animal (cat.) | Human, Dog, In vitro |
Toxicology Major finding | Subcutaneous Drug Administration in Pediatric Palliative Home Care: A Multicenter Prospective Study.. Pediatric palliative care patients frequently present with complex, life-limiting conditions and a high symptom burden requiring effective therapeutic strategies. The subcutaneous route is an important alternative for symptom control care when enteral or intravenous administration is not feasible.… |
Clinical Safety signal | Subcutaneous Drug Administration in Pediatric Palliative Home Care: A Multicenter Prospective Study.. Pediatric palliative care patients frequently present with complex, life-limiting conditions and a high symptom burden requiring effective therapeutic strategies. The subcutaneous route is an important alternative for symptom control care when enteral or intravenous administration is not feasible.… |
Clinical Program phase | PHASE_1 |
Clinical Trial activity | No active/completed counts |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | midazolam |
Overview Company | Alterome Therapeutics, Inc. |
Overview Modality | ADC |
Overview Target | Carcinomas |
Overview Indication | Cancer; PDAC - Pancreatic Ductal Adenocarcinoma |
Overview Phase | PHASE_1 |
Overview Status | ACTIVE |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
MoA Mechanism | ADC decoupling, FcRn recycling, target-mediated drug disposition, and lysosomal MMAE release |
MoA Biomarker | Biomarker Data |
PK/PD Species | Dog, Minipig |
PK/PD Animal (cat.) | Human, Dog, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Dog, Minipig |
Toxicology Animal (cat.) | Human, Dog, In vitro |
Toxicology Major finding | Subcutaneous Drug Administration in Pediatric Palliative Home Care: A Multicenter Prospective Study.. Pediatric palliative care patients frequently present with complex, life-limiting conditions and a high symptom burden requiring effective therapeutic strategies. The subcutaneous route is an important alternative for symptom control care when enteral or intravenous administration is not feasible.… |
Clinical Safety signal | Subcutaneous Drug Administration in Pediatric Palliative Home Care: A Multicenter Prospective Study.. Pediatric palliative care patients frequently present with complex, life-limiting conditions and a high symptom burden requiring effective therapeutic strategies. The subcutaneous route is an important alternative for symptom control care when enteral or intravenous administration is not feasible.… |
Clinical Program phase | PHASE_1 |
Clinical Trial activity | No active/completed counts |
추천 비교
추천 비교